Who
Curtis Lockshin
Director
Company insider
Files Form 4 as: Director, Phio Pharmaceuticals; Chief Sciencific Officer, Xenetic Biosciences; Director, Niagen Bioscience; Director, Sorrento Therapeutics; Director, Winston Pharmaceuticals.
In numbers
- Trades disclosed
- 34
- Buys
- 1
- Sells
- 0
- Bought
- $3,700
- Sold
- $0
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 21 Sep 2009
- Last trade
- 5 Feb 2026
- Last filed
- 6 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Feb 2026filed 6 Feb 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,600 at $0.00 | filing |
| 5 Feb 2026filed 6 Feb 2026 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,600 at $0.00 | filing |
| 11 Sep 2025filed 15 Sep 2025 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —16,200 at $0.00 | filing |
| 11 Sep 2024filed 12 Sep 2024 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 11 Dec 2023filed 13 Dec 2023 | XBIO Xenetic Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 17 Feb 2023filed 22 Feb 2023 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —1,500 at $0.00 | filing |
| 24 Mar 2022filed 28 Mar 2022 | XBIO Xenetic Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 15 Feb 2022filed 16 Feb 2022 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 18 Mar 2021filed 22 Mar 2021 | XBIO Xenetic Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 1 Mar 2021filed 3 Mar 2021 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 4 Dec 2019filed 6 Dec 2019 | XBIO Xenetic Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —90,000 at $0.00 | filing |
| 13 Feb 2019filed 15 Feb 2019 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Aug 2018filed 3 Aug 2018 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 1 Feb 2017filed 3 Feb 2017 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,000 at $0.00 | filing |
| 10 Feb 2016filed 12 Feb 2016 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,666 at $0.00 | filing |
| 2 Jun 2015filed 3 Jun 2015 | PHIO Phio PharmaceuticalsBiotechnology | SEC FORM 4 Code A | $4,80012,000 at $0.40 | filing |
| 2 Jun 2015filed 3 Jun 2015 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 2 Jun 2015filed 3 Jun 2015 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,000 at $0.00 | filing |
| 1 Jun 2015filed 2 Jun 2015 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,666 at $0.00 | filing |
| 2 Jun 2014filed 4 Jun 2014 | PHIO Phio Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,666 at $0.00 | filing |
News
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow SeriesPHIO · standard-freeholder.com · 19 Oct 2026
0 headlines in the last 90 days name Curtis Lockshin; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.